Article
Author(s):
San Francisco - Individualization of drug therapy is becoming a reality with the recognition that the response to drugs varies as a result of sequence variants in genes encoding drug-metabolizing enzymes, drug transporters, or drug targets.
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
MCADT Model Advances Melanoma Detection
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
MiDerm App Intervention Serves as Beneficial Platform for Adults With Skin Conditions to Find Community, Support
The Weekly Roundup: January 5 – 11